EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy

Emma Ortiz-Islas iD, Pedro Montes, Citlali Ekaterina Rodríguez-Pérez, Elizabeth Ruiz-Sánchez, Talía Sánchez-Barbosa, Diego Pichardo-Rojas iD, Cecilia Zavala-Tecuapetla iD, Karla Carvajal-Aguilera, Victoria Campos-Peña iD

Pharmaceutics · 17.01.2025 · 17 (1) · 128

DOI: 10.3390/pharmaceutics17010128 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 17.01.2025. Verfasst von Emma Ortiz-Islas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Neurofarmacologia Molecular y Nanotecnologia, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 1426…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 435 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ciencia de Frontera.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) represents an escalating global health crisis, constituting the leading cause of dementia among the elderly and profoundly impairing their quality of life. Current FDA-approved drugs, such as rivastigmine, donepezil, galantamine, and memantine, offer only modest symptomatic relief and are frequently associated with significant adverse effects. Faced with this challenge and in line with advances in the understanding of the pathophysiology of this neurodegenerative condition, various innovative therapeutic strategies have been explored. Here, we review novel approaches inspired by advanced knowledge of the underlying pathophysiological mechanisms of the disease. Among the therapeutic alternatives, immunotherapy stands out, employing monoclonal antibodies to specifically target and eliminate toxic proteins implicated in AD. Additionally, the use of medicinal plants is examined, as their synergistic effects among components may confer neuroprotective properties. The modulation of the gut microbiota is also addressed as a peripheral strategy that could influence neuroinflammatory and degenerative processes in the brain. Furthermore, the therapeutic potential of emerging approaches, such as the use of microRNAs to regulate key cellular processes and nanotherapy, which enables precise drug delivery to the central nervous system, is analyzed. Despite promising advances in these strategies, the incidence of Alzheimer’s disease continues to rise. Therefore, it is proposed that achieving effective treatment in the future may require the integration of combined approaches, maximizing the synergistic effects of different therapeutic interventions.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseasefecal microbiota transplantationimmunotherapymedicinal plantsmiRNAsnanotechnologyprobiotics

Autor:innen und Institutionen

  • Laboratorio de Neurofarmacologia Molecular y Nanotecnologia, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.
  • Laboratorio de Neuroinmunoendocrinología, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.
  • Laboratorio de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.
  • Laboratorio Experimental de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.
  • Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City 07360, Mexico.
  • Programa Prioritario de Epilepsia, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.

ORCID-Profile: Emma Ortiz-Islas, Diego Pichardo-Rojas, Cecilia Zavala-Tecuapetla, Victoria Campos-Peña

Förderung

  • Ciencia de Frontera

Zitieren

APA

Ortiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala-Tecuapetla, C., Carvajal-Aguilera, K., & Campos-Peña, V. (2025). Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy. Pharmaceutics, 17(1), 128. https://doi.org/10.3390/pharmaceutics17010128

Vancouver

Ortiz-Islas E, Montes P, Rodríguez-Pérez CE, Ruiz-Sánchez E, Sánchez-Barbosa T, Pichardo-Rojas D, et al. Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy. Pharmaceutics. 2025;17(1):128. doi:10.3390/pharmaceutics17010128

BibTeX
@article{OrtizIslas2025,
  author = {Ortiz-Islas, Emma and Montes, Pedro and Rodríguez-Pérez, Citlali Ekaterina and Ruiz-Sánchez, Elizabeth and Sánchez-Barbosa, Talía and Pichardo-Rojas, Diego and Zavala-Tecuapetla, Cecilia and Carvajal-Aguilera, Karla and Campos-Peña, Victoria},
  title = {Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {1},
  pages = {128},
  doi = {10.3390/pharmaceutics17010128}
}
Kostenlos starten →